Open AccessClinical experience of bilastine treatment in patients suffering from allergic diseases
Author(s) -
O G Elisyutina,
Е С Феденко,
О В Штырбул,
E N Zemskaya,
Alla Litovkina,
Evgenii Smolnikov
Publication year - 2018
Publication title -
rossijskij allergologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2686-682X
pISSN - 1810-8830
DOI - 10.36691/rja163
Subject(s) - medicine , dermatology , chronic idiopathic urticaria , clinical efficacy , chronic urticaria , allergy , immunology
The results of clinical observation of 60 patients with urticaria (n=30) and perennial allergic rhinitis (n=30) aged from 12 to 61 years old are presented. All patients were treated with bilastine 20 mg once a day during 30 days. The assessment of urticaria activity score (UAS, UAS7), nasal and non nasal symptoms severity score of allergic rhinitis has been performed before, 2 weeks and 4 weeks of the treatment. The majority of patients demonstrated control of disease symptoms. The efficacy and safety of bilastine 20 mg in chronic spontaneous and acute urticaria as well as allergic rhinitis was shown.